Second Generation Patents in Pharmaceutical Innovation
The development of new medications and improvements thereof are crucial to ensure continued gains in health. The development process is long and costly, and mainly to produce the information to meet high regulatory requirements. In contrast, imitation involves negligible costs and much reduced risks...
Kaydedildi:
Yazar: | Ahn, Hyewon (auth) |
---|---|
Materyal Türü: | Elektronik Kitap Bölümü |
Dil: | İngilizce |
Baskı/Yayın Bilgisi: |
Nomos Verlagsgesellschaft mbH & Co. KG
2014
|
Seri Bilgileri: | Munich Intellectual Property Law Center - MIPLC
|
Konular: | |
Online Erişim: | DOAB: download the publication DOAB: description of the publication |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Benzer Materyaller
-
Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions
Yazar:: Ahn, Hyewon
Baskı/Yayın Bilgisi: (2011) -
Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?
Yazar:: Donghi, Monica
Baskı/Yayın Bilgisi: (2014) -
The Role of the Patent System in Stimulating Innovation and Technology Transfer for Climate Change Including Aspects of Licensing and Competition Law
Yazar:: Kim, Hee-Eun
Baskı/Yayın Bilgisi: (2011) -
Patenting Proteomics Patentability and Scope of Protection of Three-Dimensional Protein Structure Claims under German, European and US law
Yazar:: Schuster, Martina
Baskı/Yayın Bilgisi: (2010) -
Patentability Requirements for Nanotechnological Inventions An Approach from the European Patent Convention Perspective
Yazar:: Cisneros, Mario
Baskı/Yayın Bilgisi: (2009)